Company Profile

RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders. The Company is focused on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from SCI, certain neurological orphan diseases and obstructive sleep apnea (OSA). The Company is developing a pipeline of new and repurposed drug products based on its patent portfolios for two drug platforms: neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or PAMs) GABAA receptors and AMPA-type glutamate receptors, respectively, and pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous systemâ€™s endogenous cannabinoid receptors.

Employees

Sector

Biotechnology & Medical Research

More about the company

11-19	RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement	CI
11-18	RespireRx Pharmaceuticals Inc. announced that it expects to receive $45 million in funding	CI
24-04-09	RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	CI
24-03-20	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	CI
24-02-13	RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	CI
24-01-22	RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	CI
24-01-04	Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	CI
23-11-17	RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-21	RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-05-22	RespireRx Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-05-21	RespireRx Pharmaceuticals Inc. announced that it has received $0.25 million in funding from ARNOLD LIPPA FAMILY TRUST OF 2007	CI
23-04-17	RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-04-16	RespireRx Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	CI

25-02-10	RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties	AQ
24-07-08	RespireRx Pharmaceuticals : Material Agreement Form 8 K	PU
24-07-04	Stocks Under 1¢: June 2024 Gains, July 2024 Watchlist SMCE, SPZI, RSPI, HALB, BIEI, RJDG	AQ
24-05-29	RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury	AQ
24-03-20	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	AQ

Manager	Title	Age	Since
Arnold Lippa CEO	Chief Executive Officer	79	2022-01-30
Jeff Margolis DFI	Director of Finance/CFO	70	2017-06-30
Richard Purcell CTO	Chief Tech/Sci/R&D Officer	65	2014-10-14

Director	Title	Age	Since
Arnold Lippa CHM	Chairman	79	2013-03-21
Jeff Margolis BRD	Director/Board Member	70	2013-03-21

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/30/20	Kathryn MacFarlane	Free	Director	5,000,000	1.6264%
9/30/20	Jeff Margolis	Conversion	Chief Financial Officer	203,810,764	66.2948%
9/30/20	Timothy Jones	Conversion	Chief Executive Officer	8,818,126	2.8683%

RespireRx Pharmaceuticals Inc. Stock

Stocks

RSPI

US7612273059

Biotechnology & Medical Research

Chart: RespireRx Pharmaceuticals Inc.

Latest news : RespireRx Pharmaceuticals Inc.

Press Releases: RespireRx Pharmaceuticals Inc.

Managers and Directors: RespireRx Pharmaceuticals Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RESPIRERX PHARMACEUTICALS INC.	-.--%	+28.57%	-	-	1.71M
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+38.10%	+74.02%	56.54B
ARGENX SE	-2.17%	-6.51%	+25.66%	+62.29%	53.6B
BIONTECH SE	+0.36%	+1.40%	-15.61%	-13.72%	22.91B
INSMED INCORPORATED	+0.77%	-7.78%	-9.28%	+352.92%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+0.15%	+0.36%	+24.28%	-14.44%	20.27B
GENMAB A/S	-0.35%	-2.28%	+31.86%	-29.13%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.45%	-7.15%	+17.96%	+554.50%	14.75B
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+162.81%	+287.77%	13.53B
EXELIXIS, INC.	-0.27%	-4.23%	+42.32%	+160.72%	13.33B
Average	-0.13%	-3.79%	+35.34%	+159.44%	25.98B
Weighted average by Cap.	+0.02%	-2.96%	+30.18%	+120.42%